drugset

drugset / Trial / NCT00225290

Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve

NCT00225290 ↗

Phase 3 Terminated 230 enrolled TTY Biopharm

RandomizedParallel-groupDouble-blindTreatment

Summary

To compare the overall survival of thalidomide- and placebo-treated advanced HCC patients.

Timeline

Start: 2003-02
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Thalidomide	Other / unclassified	—	Oral

Indications